THE SYNDROME OF CONSTANT HUNGER

Monika Rajs; Patrycja Przebieradło; Patrycja Rędzianiak; Sandra Żak; Alicja Ruzik; Antonina Gaj-Hunter; Monika Kowalska; Katarzyna Żurek; Kaja Stolarska; Sandra Terpiłowska

doi:10.31435/ijitss.2(50).2026.5504

Authors

Monika Rajs University of Rzeszow, Faculty of Medicine, Rzeszow, Poland https://orcid.org/0009-0004-3368-0847
Patrycja Przebieradło University of Rzeszow, Faculty of Medicine, Rzeszow, Poland https://orcid.org/0009-0005-7583-1890
Patrycja Rędzianiak University of Rzeszow, Faculty of Medicine, Rzeszow, Poland https://orcid.org/0000-0002-2301-3192
Sandra Żak Jan Kochanowski University in Kielce, Faculty of Medicine, Kielce, Poland https://orcid.org/0009-0009-0227-6899
Alicja Ruzik Jan Kochanowski University in Kielce, Faculty of Medicine, Kielce, Poland https://orcid.org/0009-0006-6072-5005
Antonina Gaj-Hunter Jan Kochanowski University in Kielce, Faculty of Medicine, Kielce, Poland https://orcid.org/0009-0009-6916-1391
Monika Kowalska Medical University of Lodz, Faculty of Medicine, Lodz, Poland https://orcid.org/0009-0004-8465-2133
Katarzyna Żurek Jan Kochanowski University in Kielce, Faculty of Medicine, Kielce, Poland https://orcid.org/0000-0002-7073-4160
Kaja Stolarska Jan Kochanowski University in Kielce, Faculty of Medicine, Kielce, Poland https://orcid.org/0009-0002-8849-1141
Sandra Terpiłowska Medical University of Warsaw, Faculty of Medicine, Warsaw, Poland https://orcid.org/0009-0007-7531-6594

DOI:

https://doi.org/10.31435/ijitss.2(50).2026.5504

Keywords:

Prader-Willi Syndrome, Obesity, Chromosome Disorder, Metabolism, Hypothalamic Disorder

Abstract

Prader–Willi syndrome (PWS) is a rare genetic disorder resulting from abnormalities in gene expression. The inability to experience satiety constitutes the major challenge faced by individuals affected by this condition. This lifelong disturbance manifests through numerous complications, including morbid obesity, hypogonadism, infertility, diabetes mellitus, hypercholesterolemia, arterial hypertension, cardiovascular diseases, obstructive sleep apnoea, degenerative joint disease, immobility and even social stigmatization due to excessive body weight.

The disease and its secondary complications significantly impair the quality of life and contribute to a reduced life expectancy. Although Prader–Willi syndrome is an uncommon clinical entity, the severity and complexity of its manifestations require continuous and coordinated efforts from physicians and healthcare professionals.

References

Whitman, B. Y. (2024). Prader-Willi syndrome: The more we know, the less we know. Missouri Medicine, 121(3), 235–241.

Sohn, Y. B., Moon, J. E., Jung, Y. J., & Yu, Y. A. (2023). Updates on obesity in Prader-Willi syndrome: From genetics to management. Ewha Medical Journal, 46(Suppl. 1), e33. https://doi.org/10.12771/emj.2023.e33

Goldstone, A. P., Holland, A. J., Hauffa, B. P., Hokken-Koelega, A. C., & Tauber, M. (2008). Recommendations for the diagnosis and management of Prader-Willi syndrome. The Journal of Clinical Endocrinology & Metabolism, 93(11), 4183–4197.

Butler, M. G., Miller, J. L., & Forster, J. L. (2019). Prader-Willi syndrome—Clinical genetics, diagnosis and treatment approaches: An update. Current Pediatric Reviews, 15(4), 207–244. https://doi.org/10.2174/1573396315666190716120925

Angulo, M. A., Butler, M. G., & Cataletto, M. E. (2015). Prader-Willi syndrome: A review of clinical, genetic, and endocrine findings. Journal of Endocrinological Investigation, 38(12), 1249–1263. https://doi.org/10.1007/s40618-015-0312-9

Drabik, M., Lewiński, A., & Stawerska, R. (2022). Management of Prader-Labhart-Willi syndrome in children and in adults, with particular emphasis on the treatment with recombinant human growth hormone. Pediatric Endocrinology Diabetes and Metabolism, 28(1), 64–74. https://doi.org/10.5114/pedm.2022.112861

Lukoshe, A., van Dijk, S. E., van den Bosch, G. E., van der Lugt, A., White, T., Hokken-Koelega, A. C. S., & Oranje, B. (2017). Altered functional resting-state hypothalamic connectivity and abnormal pituitary morphology in children with Prader-Willi syndrome. Journal of Neurodevelopmental Disorders, 9(1), Article 12. https://doi.org/10.1186/s11689-017-9188-7

Brown, S. S. G., Manning, K. E., Fletcher, P., & Holland, A. (2022). In vivo neuroimaging evidence of hypothalamic alteration in Prader-Willi syndrome. Brain Communications, 4(5), fcac229.

Voevodskaya, O., Simmons, A., Nordenskjöld, R., Kullberg, J., Ahlström, H., Lind, L., Wahlund, L.-O., Larsson, E.-M., Westman, E., & Alzheimer’s Disease Neuroimaging Initiative. (2014). The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer’s disease. Frontiers in Aging Neuroscience, 6, Article 264.

Tournier, J.-D., Smith, R., Raffelt, D., Tabbara, R., Dhollander, T., Pietsch, M., Christiaens, D., Jeurissen, B., Yeh, C.-H., & Connelly, A. (2019). MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation. NeuroImage, 202, Article 116137.

Dell’Acqua, F., & Tournier, J.-D. (2019). Modelling white matter with spherical deconvolution: How and why? NMR in Biomedicine, 32(4), e3945.

Driscoll, D. J., Miller, J. L., & Cassidy, S. B. (1998). Prader-Willi syndrome. In M. P. Adam, J. Feldman, G. M. Mirzaa, et al. (Eds.), GeneReviews®. University of Washington, Seattle. Updated December 5, 2024. https://www.ncbi.nlm.nih.gov/books/NBK1330/

Grugni, G., Sartorio, A., & Crinò, A. (2016). Growth hormone therapy for Prader-Willi syndrome: Challenges and solutions. Therapeutics and Clinical Risk Management, 12, 873–881. https://doi.org/10.2147/TCRM.S70068

Muscogiuri, G., Barrea, L., Faggiano, F., Maiorino, M. I., Parrillo, M., Pugliese, G., Ruggeri, R. M., Scarano, E., Savastano, S., & Colao, A. (2021). Obesity in Prader-Willi syndrome: Physiopathological mechanisms, nutritional and pharmacological approaches. Journal of Endocrinological Investigation, 44, 2057–2070. https://doi.org/10.1007/s40618-021-01574-9

Crinò, A., Fintini, D., Bocchini, S., & Grugni, G. (2018). Obesity management in Prader-Willi syndrome: Current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 11, 579–593. https://doi.org/10.2147/DMSO.S141352

Buiting, K., Gross, S., Lich, C., Gillessen-Kaesbach, G., el-Maarri, O., & Horsthemke, B. (2003). Epimutations in Prader-Willi and Angelman syndromes: A molecular study of 136 patients with an imprinting defect. American Journal of Human Genetics, 72(3), 571–577. https://doi.org/10.1086/367926

Luccarelli, J. (2022). Demographics and medical comorbidities among hospitalized patients with Prader-Willi syndrome: A National Inpatient Sample analysis. American Journal of Medical Genetics Part A, 188(10), 2899–2907. https://doi.org/10.1002/ajmg.a.62901

Cassidy, S. B., Schwartz, S., Miller, J. L., & Driscoll, D. J. (2012). Prader-Willi syndrome. Genetics in Medicine, 14(1), 10–26. https://doi.org/10.1038/gim.0b013e31822bead0

Hedgeman, E., Ulrichsen, S. P., Carter, S., Kreher, N. C., Malobisky, K. P., Braun, M. M., Fryzek, J., & Olsen, M. S. (2017). Long-term health outcomes in patients with Prader-Willi syndrome: A nationwide cohort study in Denmark. International Journal of Obesity, 41(10), 1531–1538. https://doi.org/10.1038/ijo.2017.139

Butler, M. G., Oyetunji, A., & Manzardo, A. M. (2020). Age distribution, comorbidities and risk factors for thrombosis in Prader-Willi syndrome. Genes, 11(1), Article 67. https://doi.org/10.3390/genes11010067

Yee, B. J., Buchanan, P. R., Mahadev, S., Banerjee, D., Ching, N., & Grunstein, R. R. (2007). Assessment of sleep and breathing in adults with Prader-Willi syndrome: A case control series. Journal of Clinical Sleep Medicine, 3(7), 713–718.